# Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

> **NCT07546981** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 554 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Experimental: Participant Group CHF 5993 pMDI HFA-152a
- **OTHER:** Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a

## Key facts

- **NCT ID:** NCT07546981
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-10-17
- **Final completion:** 2028-10-17
- **Target enrollment:** 554 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07546981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07546981, "Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07546981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*